Bioresorbable Scaffold Thrombosis: incidence, risk factors and possible mechanism

Original Title: Bioresorbable Vascular Scaffold Thrombosis. Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. Reference: Puricel S et al. J Am Coll Cardiol 2016;67:921-31.

Courtesy of Dr. Guillermo Migliaro.

Bioresorbable scaffolds (BVS) were introduced in interventional cardiology to avoid late DES complications. However, recent reports suggest an elevated incidence of thrombosis with these new devices.

The referred article is a registry carried out in 4 centers including 1305 consecutive patients undergoing PCI with BVS in de novo lesions both for ACS and stable heart disease. Mean age was 64 and 78% were men. In this group of patients, thrombosis frequency and clinical and angiographic characteristics were analyzed to determine the possible mechanisms involved.

Thrombosis occurred in 42 patients. Probable/definite thrombosis incidence was 1.8% at 30 days and 3% at 12 months with no differences across centers (p=0.60).

In 52% of cases, thrombosis presented as ST elevation AMI and 17% as sudden death.

Multivariable analysis of ostial lesions (p=0.049) and depressed ejection fraction (p=0.019) were independently associated to thrombosis.

hrombosis presented in 21% of patients that had stopped dual antiaggregation therapy, mostly before the first year. As regards angiographic variables, post procedural lower reference vessel and minimum lumen diameters were independent predictors of thrombosis (p<0.001).

These finding strongly suggest that underexpansion or incomplete malapposition could be the underlying mechanisms of thrombosis.

When implementing an implantation strategy, considering aggressive pre and post dilation with non-compliant balloons up to 0.5 mm larger than the BVS, thrombosis incidence dropped to 1%, which equals a 70% reduction in thrombosis incidence, when comparing both groups (p=0.012)

Conclusion
Thrombosis incidence in BVS is 3% at 12 months, though it could significantly reduce when using the adequate implantation strategy. Other thrombosis predictors were ostial lesions and depressed ventricular function, post procedural lower vessel and minimum lumen diameters. These last two findings suggest that the mechanism involved could be stent underexpansion.

Editorial Comment
This registry is not randomized and has a small number of events, which is why the mechanisms involved should be interpreted with caution. This study does not contemplate the use of intracoronary images for stent collocation, such as OCT.

Courtesy of Dr. Guillermo Migliaro.

 

Imagen: Abbott Vascular

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...